gliclazide has been researched along with Fasting Hypoglycemia in 47 studies
Gliclazide: An oral sulfonylurea hypoglycemic agent which stimulates insulin secretion.
Fasting Hypoglycemia: HYPOGLYCEMIA expressed in the postabsorptive state, after prolonged FASTING, or an overnight fast.
Excerpt | Relevance | Reference |
---|---|---|
"Patients treated with either gliclazide or DPP-4 inhibitors while fasting during Ramadan have similarly low risks of experiencing symptomatic hypoglycemia." | 8.91 | Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach. ( Abdel-Rahim, A; Al-Sifri, S; Mbanya, JC; Satman, I, 2015) |
"Initiation of iGlarLixi resulted in similar TIR, A1C, FPG, weight and hypoglycemia compared with the more affordable option of starting iGlar + gliclazide in adults of South Asian origin with T2D." | 5.51 | Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial. ( Aronson, R; Bajaj, HS; Bansal, N; Bhela, JS; Brown, RE; Chu, L; Dhillon, G; Gupta, R; Khandwala, H; Padda, JK; Venn, K, 2022) |
"Several observational studies were conducted with vildagliptin in patients with type 2 diabetes mellitus (T2DM) fasting during Ramadan, showing significantly lower incidences of hypoglycemia with vildagliptin versus sulfonylureas, including gliclazide." | 5.19 | A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study. ( Abdallah, K; Hassanein, M; Schweizer, A, 2014) |
"Patients treated with either gliclazide or DPP-4 inhibitors while fasting during Ramadan have similarly low risks of experiencing symptomatic hypoglycemia." | 4.91 | Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach. ( Abdel-Rahim, A; Al-Sifri, S; Mbanya, JC; Satman, I, 2015) |
"Compared with other oral insulinotropic agents, gliclazide significantly reduced HbA1c with no difference regarding hypoglycemia risk." | 4.91 | Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents. ( Chan, SP; Colagiuri, S, 2015) |
"Included were randomized studies of at least 12 weeks duration with the following outcomes: HbA1c change, incidence of severe hypoglycemia, weight change, cardiovascular events and/or mortality when comparing gliclazide with other oral blood glucose lowering drugs." | 4.90 | Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials. ( Bilo, HJ; de Bock, GH; Gans, RO; Groenier, KH; Houweling, ST; Kleefstra, N; Landman, GW; van Dijk, PR; van Hateren, KJ, 2014) |
"The risk for hypoglycemia when taking glyburide compared with modified-release gliclazide remains to be established in older adults in routine care." | 3.81 | The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide. ( Clemens, KK; Dixon, SN; Fleet, JL; Garg, AX; Hramiak, I; McArthur, E, 2015) |
"Severe hypoglycemia was strongly associated with increased risks of a range of adverse clinical outcomes." | 2.75 | Severe hypoglycemia and risks of vascular events and death. ( Billot, L; Chalmers, J; de Galan, BE; Grobbee, DE; Heller, S; Kengne, AP; Li, Q; MacMahon, S; Marre, M; Neal, B; Ninomiya, T; Patel, A; Woodward, M; Zoungas, S, 2010) |
"In patients with type 2 diabetes, the effects of intensive glucose control on vascular outcomes remain uncertain." | 2.73 | Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. ( Billot, L; Bompoint, S; Chalmers, J; Cooper, M; de Galan, BE; Glasziou, P; Grobbee, D; Hamet, P; Harrap, S; Heller, S; Joshi, R; Liu, L; MacMahon, S; Mancia, G; Marre, M; Mogensen, CE; Neal, B; Pan, C; Patel, A; Poulter, N; Rodgers, A; Travert, F; Williams, B; Woodward, M, 2008) |
"Treatment with nateglinide plus metformin for up to 12 months was not associated with weight gain." | 2.73 | Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. ( Collober-Maugeais, C; Cressier, F; Pecher, E; Ristic, S; Tang, P, 2007) |
" We sought to estimate individual beneficial and adverse effects of intensive glucose control in patients with type 2 diabetes." | 1.43 | Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes. ( Chalmers, J; Grobbee, DE; Harrap, S; Heller, S; Mancia, G; Marre, M; Poulter, N; van der Graaf, Y; van der Leeuw, J; Visseren, FL; Woodward, M; Zoungas, S, 2016) |
"Gliclazide or metformin-treated patients demonstrated lesser mortality risk than glibenclamide-treated ones in all four evaluation models, but age and duration stratification can influence this phenomenon in case of "first prescription model"." | 1.40 | Evaluation approach can significantly influence oral glucose-lowering drugs total mortality risks in retrospective cohorts of type 2 diabetes mellitus patients. ( Khalangot, M; Kovtun, V, 2014) |
"A 74-year-old woman with type 2 diabetes mellitus who had been treated with a sulfonylurea for 6 years began experiencing frequent episodes of hypoglycemia." | 1.34 | Insulinoma causing hypoglycemia in a patient with type 2 diabetes. ( Chang, WH; Chen, TL; Lei, WY; Wang, CY; Wang, TE; Yang, TL, 2007) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 3 (6.38) | 18.7374 |
1990's | 7 (14.89) | 18.2507 |
2000's | 15 (31.91) | 29.6817 |
2010's | 19 (40.43) | 24.3611 |
2020's | 3 (6.38) | 2.80 |
Authors | Studies |
---|---|
Bajaj, HS | 1 |
Chu, L | 1 |
Bansal, N | 1 |
Brown, RE | 1 |
Dhillon, G | 1 |
Gupta, R | 1 |
Bhela, JS | 1 |
Padda, JK | 1 |
Khandwala, H | 1 |
Venn, K | 1 |
Aronson, R | 1 |
Kelty, E | 1 |
Tran, DD | 1 |
Atkinson, A | 1 |
Preen, DB | 1 |
Havard, A | 1 |
Mifsud, S | 1 |
Schembri, EL | 1 |
Fava, S | 1 |
Saberi, M | 1 |
Ramazani, Z | 1 |
Rashidi, H | 1 |
Saberi, A | 1 |
Raslan, IA | 1 |
McDonald, EG | 1 |
Lee, TC | 1 |
Gopal-Kothandapani, JS | 1 |
Wright, KP | 1 |
Sithambaram, S | 1 |
Natarajan, A | 1 |
Douros, A | 1 |
Yin, H | 1 |
Yu, OHY | 1 |
Filion, KB | 1 |
Azoulay, L | 1 |
Suissa, S | 1 |
Landman, GW | 2 |
de Bock, GH | 1 |
van Hateren, KJ | 2 |
van Dijk, PR | 1 |
Groenier, KH | 2 |
Gans, RO | 1 |
Houweling, ST | 1 |
Bilo, HJ | 1 |
Kleefstra, N | 2 |
Winkler, G | 1 |
Hassanein, M | 2 |
Abdallah, K | 1 |
Schweizer, A | 1 |
Zhao, F | 1 |
Ma, YF | 1 |
Wen, JX | 1 |
DU, YF | 1 |
Li, CL | 1 |
Li, GW | 1 |
Khalangot, M | 1 |
Kovtun, V | 1 |
Clemens, KK | 1 |
McArthur, E | 1 |
Dixon, SN | 1 |
Fleet, JL | 1 |
Hramiak, I | 1 |
Garg, AX | 1 |
Mbanya, JC | 1 |
Al-Sifri, S | 1 |
Abdel-Rahim, A | 1 |
Satman, I | 1 |
Chan, SP | 1 |
Colagiuri, S | 1 |
Oei, E | 1 |
Samad, N | 1 |
Visser, A | 1 |
Chowdhury, TA | 2 |
Fan, SL | 1 |
Wong, MG | 1 |
Perkovic, V | 1 |
Chalmers, J | 5 |
Woodward, M | 5 |
Li, Q | 2 |
Cooper, ME | 1 |
Hamet, P | 3 |
Harrap, S | 3 |
Heller, S | 4 |
MacMahon, S | 4 |
Mancia, G | 4 |
Marre, M | 4 |
Matthews, D | 1 |
Neal, B | 4 |
Poulter, N | 4 |
Rodgers, A | 2 |
Williams, B | 2 |
Zoungas, S | 4 |
van der Leeuw, J | 1 |
Visseren, FL | 1 |
van der Graaf, Y | 1 |
Grobbee, DE | 3 |
van Dijk, P | 1 |
Bouma, A | 1 |
Bilo, H | 1 |
Patel, A | 3 |
Billot, L | 2 |
Cooper, M | 2 |
Glasziou, P | 1 |
Grobbee, D | 1 |
Liu, L | 1 |
Mogensen, CE | 1 |
Pan, C | 1 |
Bompoint, S | 1 |
de Galan, BE | 3 |
Joshi, R | 1 |
Travert, F | 2 |
Walker, J | 1 |
White, R | 1 |
Vale, A | 1 |
Elliott, S | 2 |
Wass, J | 1 |
Reynolds, J | 1 |
Devendra, D | 1 |
Gohel, B | 1 |
Bravis, V | 1 |
Hui, E | 1 |
Salih, S | 1 |
Mehar, S | 1 |
Anderson, C | 1 |
Dufouil, C | 1 |
Pillai, A | 1 |
Hackett, M | 1 |
Heller, SR | 1 |
Lisheng, L | 1 |
Pan, CY | 1 |
Ling, GR | 1 |
Singh, K | 1 |
Wong, SY | 1 |
Toh, VK | 1 |
Ninomiya, T | 1 |
Kengne, AP | 1 |
Gupta, PS | 1 |
Green, AN | 1 |
Ragia, G | 1 |
Tavridou, A | 1 |
Petridis, I | 1 |
Manolopoulos, VG | 1 |
Langford, NJ | 1 |
Krentz, AJ | 1 |
Martin, U | 1 |
Ferner, RE | 1 |
Crawford, BA | 1 |
Perera, C | 1 |
Schernthaner, G | 1 |
Grimaldi, A | 1 |
Di Mario, U | 1 |
Drzewoski, J | 1 |
Kempler, P | 1 |
Kvapil, M | 1 |
Novials, A | 1 |
Rottiers, R | 1 |
Rutten, GE | 1 |
Shaw, KM | 1 |
Satyanarayana, S | 1 |
Sekhar, JR | 1 |
Kumar, KE | 1 |
Shannika, LB | 1 |
Rajanna, B | 1 |
Rajanna, S | 1 |
Chan, HY | 1 |
Tiu, SC | 1 |
Chan, OK | 1 |
Lei, WY | 1 |
Wang, TE | 1 |
Chen, TL | 1 |
Chang, WH | 1 |
Yang, TL | 1 |
Wang, CY | 1 |
Ristic, S | 1 |
Collober-Maugeais, C | 1 |
Cressier, F | 1 |
Tang, P | 1 |
Pecher, E | 1 |
Sener, A | 1 |
Akkan, AG | 1 |
Malaisse, WJ | 1 |
Tessier, D | 1 |
Dawson, K | 1 |
Tétrault, JP | 1 |
Bravo, G | 1 |
Meneilly, GS | 1 |
Braatvedt, GD | 1 |
van Staa, T | 1 |
Abenhaim, L | 1 |
Monette, J | 1 |
Paroni, R | 1 |
Comuzzi, B | 1 |
Arcelloni, C | 1 |
Brocco, S | 1 |
de Kreutzenberg, S | 1 |
Tiengo, A | 2 |
Ciucci, A | 1 |
Beck-Peccoz, P | 1 |
Genovese, S | 1 |
da Tos, V | 1 |
Maran, A | 1 |
Vigili de Kreutzenberg, S | 1 |
Marchetto, S | 1 |
Tadiotto, F | 1 |
Bettio, M | 1 |
Marescotti, MC | 1 |
Del Prato, S | 1 |
Abad, S | 1 |
Moachon, L | 1 |
Blanche, P | 1 |
Bavoux, F | 1 |
Sicard, D | 1 |
Salmon-Céron, D | 1 |
De Vigan, C | 1 |
Delporte, MP | 1 |
Thomas, M | 1 |
Perrault, M | 1 |
Grandmottet, P | 1 |
Narboni, G | 1 |
Schwager, JC | 1 |
Betchel, P | 1 |
Sandoz, M | 1 |
Vandel, B | 1 |
de Lavenne, P | 1 |
Peijnenburg, MA | 1 |
Shenfield, GM | 1 |
Boutagy, JS | 1 |
Webb, C | 1 |
Archambeaud-Mouveroux, F | 1 |
Nouaille, Y | 1 |
Nadalon, S | 1 |
Treves, R | 1 |
Merle, L | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Variability of Glucose Assessed in a Randomized Trial Comparing the Initiation of A Treatment Approach With Biosimilar Basal Insulin Analog Or a Titratable iGlarLixi combinatioN in Type 2 Diabetes Among South Asian Subjects (VARIATION 2 SA Trial)[NCT03819790] | Phase 4 | 119 participants (Actual) | Interventional | 2018-10-02 | Completed | ||
A Double Blind, Double Dummy, Randomised, Multi-centre Study to Assess the Tolerability and Efficacy Profile of Vildagliptin Compared to Gliclazide as Dual Therapy With Metformin in Muslim Patients With Type 2 Diabetes Fasting During Ramadan[NCT01758380] | Phase 4 | 557 participants (Actual) | Interventional | 2013-01-31 | Completed | ||
Action in Diabetes and Vascular Disease Preterax and Diamicron MR Controlled Evaluation Post Trial Observational Study[NCT00949286] | 8,494 participants (Actual) | Observational | 2010-01-31 | Completed | |||
ADVANCE - Action in Diabetes and Vascular Disease: Preterax and Diamicron - MR Controlled Evaluation[NCT00145925] | Phase 3 | 11,140 participants (Actual) | Interventional | 2001-06-30 | Completed | ||
Carotid Intimae-media Thickness (CIMT) and Carotid Plaque (CP) Presence as Risk Markers of Cardiovascular Disease at the Time of Type 2 Diabetes Diagnosis[NCT01898572] | 200 participants (Anticipated) | Observational | 2012-01-31 | Active, not recruiting | |||
Low-dose Colchicine Intervention in Patients With Type 2 Diabetes Mellitus and Microalbuminuria: Chongqing Study[NCT02035891] | 160 participants (Actual) | Interventional | 2013-12-31 | Active, not recruiting | |||
Effect of Anti-diabetic Drugs on Glycemic Variability. A Comparison Between Gliclazide MR (Modified Release) and Dapagliflozin on Glycemic Variability Measured by Continuous Glucose Monitoring (CGM) in Patients With Uncontrolled Type 2 Diabetes[NCT02925559] | Phase 4 | 135 participants (Actual) | Interventional | 2016-10-31 | Completed | ||
Effectiveness and Tolerability of Novel, Initial Triple Combination Therapy With Xigduo (Dapagliflozin Plus Metformin) and Saxagliptin vs. Conventional Stepwise add-on Therapy in Drug-naïve Patients With Type 2 Diabetes[NCT02946632] | Phase 3 | 104 participants (Anticipated) | Interventional | 2016-12-31 | Not yet recruiting | ||
Dietary Intervention in Type-2 Diabetics and Pre-Diabetics Emphasizing Personalized Carbohydrate Intake[NCT02519309] | 465 participants (Actual) | Interventional | 2015-08-31 | Completed | |||
Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
FLAT-SUGAR: FLuctuATion Reduction With inSULin and Glp-1 Added togetheR[NCT01524705] | Phase 4 | 102 participants (Actual) | Interventional | 2012-08-31 | Completed | ||
Dipeptidyl Peptidase-4 Inhibition in Psoriasis Patients With Diabetes (DIP): A Randomized Clinical Trial.[NCT01991197] | Phase 2 | 20 participants (Actual) | Interventional | 2014-04-30 | Completed | ||
A Comparison of Strict Glucose Control With Usual Care at the Time of Islet Cell Transplantation[NCT01123122] | 0 participants (Actual) | Interventional | 2011-09-30 | Withdrawn | |||
Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213] | Phase 4 | 60 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
The change in the coefficient of variation (CV) of continuous glucose readings, as assessed by Continuous Glucose Monitoring (CGM) (NCT01524705)
Timeframe: At baseline, 6 months of intervention
Intervention | percentage (Mean) |
---|---|
Insulin Glargine, Metformin, Exenatide | -2.43 |
Insulin Glargine, Metformin, Prandial Insulin | 0.44 |
% of glycosylated hemoglobin in whole blood at 26 weeks (NCT01524705)
Timeframe: Baseline vs 26 weeks
Intervention | % of HbA1C (Mean) |
---|---|
Insulin Glargine, Metformin, Exenatide | 7.1 |
Insulin Glargine, Metformin, Prandial Insulin | 7.2 |
Severe hypoglycemia-documented glucose <50mg/dl (participant journal), and hypoglycemic attacks requiring hospitalization, or treatment by emergency personnel. (NCT01524705)
Timeframe: 26 weeks
Intervention | Participants (Count of Participants) |
---|---|
Insulin Glargine, Metformin, Exenatide | 0 |
Insulin Glargine, Metformin, Prandial Insulin | 0 |
Weight in kg at 26 weeks minus weight at baseline. (NCT01524705)
Timeframe: Baseline vs 26 weeks
Intervention | kg (Mean) |
---|---|
Insulin Glargine, Metformin, Exenatide | -4.8 |
Insulin Glargine, Metformin, Prandial Insulin | 0.7 |
High sensitivity C-reactive protein (range 0 - no maximum) (NCT01991197)
Timeframe: 16 weeks
Intervention | µg/ml (Median) |
---|---|
Sitagliptin | 0 |
Gliclazide | 8.4 |
The change in glucose from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks
Intervention | mmol/L (Median) |
---|---|
Sitagliptin | -0.2 |
Gliclazide | -0.1 |
The change in systolic blood pressure from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks
Intervention | mmHg (Median) |
---|---|
Sitagliptin | 4 |
Gliclazide | -9 |
The change in total cholesterol from baseline to 16 weeks (NCT01991197)
Timeframe: 16 weeks
Intervention | mmol/L (Median) |
---|---|
Sitagliptin | 0.1 |
Gliclazide | -0.1 |
Psoriasis area and severity index 0-72, higher score worse outcome (NCT01991197)
Timeframe: baseline and 32 weeks
Intervention | score on a scale (Median) |
---|---|
Sitagliptin | 3 |
Gliclazide | 1.8 |
Psoriasis area and severity index (0-72), higher scores worse outcome (NCT01991197)
Timeframe: 16 weeks
Intervention | score on a scale (Median) |
---|---|
Sitagliptin | 9.5 |
Gliclazide | 9.4 |
The change in weight from baseline to 16 weeks measured in kg (NCT01991197)
Timeframe: 16 weeks
Intervention | kg (Median) |
---|---|
Sitagliptin | -0.5 |
Gliclazide | -0.6 |
Dipeptidyl peptidase-4 levels levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks
Intervention | dCt (Median) |
---|---|
Gliclazide | -1.12 |
Sitagliptin | 0 |
Interleukin 17 levels in skin (0-no maximum) (NCT01991197)
Timeframe: 16 weeks
Intervention | dCt (Median) |
---|---|
Sitagliptin | 3.41 |
Gliclazide | 2.09 |
"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-17 (IL-17) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
Intervention | pg/ml (Median) |
---|---|
Sitagliptin | 0 |
Gliclazide | 0 |
"Secondary outcomes:~The change in serum concentrations of the cytokine interleukin-23 (IL-23) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
Intervention | pg/ml (Median) |
---|---|
Sitagliptin | 0 |
Gliclazide | 0 |
"Secondary outcomes:~The change in serum concentrations of the adipokine leptin Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
Intervention | pg/ml (Median) |
---|---|
Sitagliptin | -0.07 |
Gliclazide | 0.43 |
"Secondary outcomes:~The change in serum concentrations of the cytokines tumour necrosis factor alpha (TNFα) Range: 0-no maximum" (NCT01991197)
Timeframe: 16 weeks
Intervention | pg/ml (Median) |
---|---|
Sitagliptin | 0 |
Gliclazide | 0 |
"Dosage: Sitagliptin: 100mg daily, or 50mg daily for participants with moderate kidney disease Gliclazide: 80-320 mg daily.~Secondary outcomes: the number participants with adverse events." (NCT01991197)
Timeframe: 32 weeks
Intervention | Participants (Count of Participants) |
---|---|
Sitagliptin | 6 |
Gliclazide | 10 |
"Dermatology life quality index (a skin related quality of life measure) (0-10), higher score worse outcome EQ-5D Euroqol 5 item quality of life index comprising 5 dimensions mobility, self-care, usual activities, pain, anxiety. An index can be derived from these 5 dimensions by conversion with a table of scores. The maximum score of 1 indicates the best health state and minimum score indicating the worst health outcome -0.594.~HADS Hospital anxiety and depression scale 0-16 for anxiety and 0-16 for depression, higher score worse outcome HAQ-8 Stanford 8 item disability scale. Scoring is from 0 (without any difficulty) to 3 (unable to do). The 8 scores from the 8 sections are summed and divided by 8. The result is the disability index (range 0-3 with 25 possible values). A" (NCT01991197)
Timeframe: 16 weeks
Intervention | score on a scale (Median) | ||||
---|---|---|---|---|---|
DLQI | HAQ-8 | HADS Anxiety | HADS Depression | EQ-5D | |
Gliclazide | -1.0 | 0.0 | 0 | 0 | -0.2 |
Sitagliptin | 0.0 | 0.0 | -1 | 0 | 0 |
"Secondary outcomes:~d. number or participants who acheived a greater than 50% reduction in PASI from baseline (PASI-50); e. number of participants who achieved PASI-75 and PASI-90." (NCT01991197)
Timeframe: 16 weeks
Intervention | Participants (Count of Participants) | ||
---|---|---|---|
PASI 50 | PASI 75 | PASI 90 | |
Gliclazide | 1 | 0 | 0 |
Sitagliptin | 1 | 0 | 0 |
5 reviews available for gliclazide and Fasting Hypoglycemia
Article | Year |
---|---|
Safety and efficacy of gliclazide as treatment for type 2 diabetes: a systematic review and meta-analysis of randomized trials.
Topics: Administration, Oral; Blood Glucose; Body Weight; Cardiovascular Diseases; Diabetes Mellitus, Type 2 | 2014 |
[The use of gliclazide in individualized sulfonylurea therapy].
Topics: Gliclazide; Humans; Hypoglycemia; Hypoglycemic Agents; Insulin-Secreting Cells; Sulfonylurea Compoun | 2014 |
Incidence of hypoglycemia in patients with type 2 diabetes treated with gliclazide versus DPP-4 inhibitors during Ramadan: A meta-analytical approach.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Fasting; Gliclazide; H | 2015 |
Systematic review and meta-analysis of the efficacy and hypoglycemic safety of gliclazide versus other insulinotropic agents.
Topics: Adult; Aged; Aged, 80 and over; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Glicl | 2015 |
[Hypoglycemia].
Topics: Algorithms; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Gliclazide; Humans; | 2011 |
10 trials available for gliclazide and Fasting Hypoglycemia
Article | Year |
---|---|
Randomized Comparison of Initiating the Fixed-Ratio Combination of iGlarLixi or Biosimilar Insulin Glargine Together With Gliclazide in Participants of South Asian Origin With Type 2 Diabetes: VARIATION 2 SA Trial.
Topics: Adult; Aged; Biosimilar Pharmaceuticals; Blood Glucose; Diabetes Mellitus, Type 2; Drug Combinations | 2022 |
A double-blind, randomized trial, including frequent patient-physician contacts and Ramadan-focused advice, assessing vildagliptin and gliclazide in patients with type 2 diabetes fasting during Ramadan: the STEADFAST study.
Topics: Adamantane; Asia; Biomarkers; Blood Glucose; Body Weight; Counseling; Diabetes Mellitus, Type 2; Dip | 2014 |
Long-term Benefits of Intensive Glucose Control for Preventing End-Stage Kidney Disease: ADVANCE-ON.
Topics: Aged; Antihypertensive Agents; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Drug Combin | 2016 |
Hypoglycemia in Frail Elderly Patients With Type 2 Diabetes Mellitus Treated With Sulfonylurea.
Topics: Aged; Aged, 80 and over; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Female; Frail Eld | 2017 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes.
Topics: Aged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diab | 2008 |
Severe hypoglycemia and risks of vascular events and death.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla | 2010 |
Severe hypoglycemia and risks of vascular events and death.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla | 2010 |
Severe hypoglycemia and risks of vascular events and death.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla | 2010 |
Severe hypoglycemia and risks of vascular events and death.
Topics: Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Female; Follow-Up Studies; Glicla | 2010 |
GUIDE study: double-blind comparison of once-daily gliclazide MR and glimepiride in type 2 diabetic patients.
Topics: Diabetes Mellitus, Type 2; Double-Blind Method; Female; Gliclazide; Glycated Hemoglobin; Humans; Hyp | 2004 |
Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results.
Topics: Aged; Cyclohexanes; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Therapy, Combination; Femal | 2007 |
Glibenclamide vs gliclazide in type 2 diabetes of the elderly.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Glyburide; Humans; Hypoglycemia; | 1994 |
Mechanisms of acute and chronic hypoglycemic action of gliclazide.
Topics: Acute Disease; Blood Glucose; C-Peptide; Chronic Disease; Diabetes Mellitus, Type 2; Gliclazide; Glu | 2000 |
32 other studies available for gliclazide and Fasting Hypoglycemia
Article | Year |
---|---|
Maternal and Neonatal Health Outcomes Associated with the Use of Gliclazide and Metformin for the Treatment of Diabetes in Pregnancy: A Record Linkage Study.
Topics: Abnormalities, Drug-Induced; Adult; Diabetes, Gestational; Female; Gliclazide; Hospitalization; Huma | 2020 |
A case of severe relapsing sulphonylurea-induced hypoglycaemia.
Topics: Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hypoglycemia; Middle Aged; Renal Insufficienc | 2019 |
The Effect of CYP2C9 Genotype Variants in Type 2 Diabetes on the Pharmacological Effectiveness of Sulfonylureas, Diabetic Retinopathy, and Nephropathy.
Topics: Biomarkers; Blood Glucose; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Type 2; Diabetic Nephropathie | 2020 |
Missed Opportunities for Deprescription: A Teachable Moment.
Topics: Aged, 80 and over; Deprescriptions; Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combina | 2017 |
Dilemma of diagnosing sulphonylurea overdose in children: deliberations and considerations before reaching a diagnosis.
Topics: Adolescent; Blood Glucose; Diagnosis, Differential; Drug Overdose; Emergency Service, Hospital; Fema | 2017 |
Pharmacologic Differences of Sulfonylureas and the Risk of Adverse Cardiovascular and Hypoglycemic Events.
Topics: Aged; Aged, 80 and over; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabetes Mellitus | 2017 |
Parsimonious model for blood glucose level monitoring in type 2 diabetes patients.
Topics: Adult; Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 2; Female; Gliclazide; | 2014 |
Evaluation approach can significantly influence oral glucose-lowering drugs total mortality risks in retrospective cohorts of type 2 diabetes mellitus patients.
Topics: Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; Metform | 2014 |
The Hypoglycemic Risk of Glyburide (Glibenclamide) Compared with Modified-Release Gliclazide.
Topics: Aged; Aged, 80 and over; Cohort Studies; Delayed-Action Preparations; Diabetes Mellitus, Type 2; Fem | 2015 |
Use of continuous glucose monitoring in patients with diabetes on peritoneal dialysis: poor correlation with HbA1c and high incidence of hypoglycaemia.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; | 2016 |
Estimation of individual beneficial and adverse effects of intensive glucose control for patients with type 2 diabetes.
Topics: Aged; Antihypertensive Agents; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Drug Combinations | 2016 |
Unexplained severe hypoglycaemia in hospital: a difficult diagnostic challenge.
Topics: Aged; Cholecystectomy; Diabetes Mellitus, Type 2; Gliclazide; Humans; Hypertension; Hypoglycemia; Ma | 2009 |
Vildagliptin therapy and hypoglycaemia in Muslim type 2 diabetes patients during Ramadan.
Topics: Adamantane; Adult; Aged; Blood Glucose; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Fastin | 2009 |
Cognitive function and risks of cardiovascular disease and hypoglycaemia in patients with type 2 diabetes: the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial.
Topics: Aged; Antihypertensive Agents; Cognition; Cognition Disorders; Diabetes Mellitus, Type 2; Diabetic A | 2009 |
Severe neuroglycopaenia secondary to severe hypoglycaemia from serendipitous overdose of gliclazide without adrenergic or autonomic response.
Topics: Blood Glucose; Drug Overdose; Gliclazide; Humans; Hypoglycemia; Hypoglycemic Agents; Male | 2009 |
Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients.
Topics: Adult; Aged; Alleles; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP2C9; Diabetes Mellitus, Typ | 2012 |
Severe relapsing sulphonylurea-induced hypoglycaemia: a diagnostic and therapeutic challenge.
Topics: Female; Gliclazide; Humans; Hypoglycemia; Hypoglycemic Agents; Middle Aged; Recurrence | 2003 |
Octreotide treatment for sulfonylurea-induced hypoglycaemia.
Topics: Aged; Blood Glucose; Diabetes Mellitus, Type 2; Gliclazide; Glyburide; Humans; Hypoglycemia; Hypogly | 2004 |
Influence of selenium (antioxidant) on gliclazide induced hypoglycaemia/anti hyperglycaemia in normal/alloxan-induced diabetic rats.
Topics: Administration, Oral; Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Drug Th | 2006 |
Dual aetiologies for hyperinsulinaemic hypoglycaemia in one patient.
Topics: Adult; Gliclazide; Humans; Hyperinsulinism; Hypoglycemia; Hypoglycemic Agents; Insulinoma; Male; Pan | 2007 |
Insulinoma causing hypoglycemia in a patient with type 2 diabetes.
Topics: Aged; Diabetes Mellitus, Type 2; Female; Gliclazide; Humans; Hyperinsulinism; Hypoglycemia; Hypoglyc | 2007 |
Standardized procedure for the assay and identification of hypoglycemic sulfonylureas in human plasma.
Topics: Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drug Monitoring; Forensic Medicine; | 1995 |
Octreotide for the treatment of sulphonylurea induced hypoglycaemia in type 2 diabetes.
Topics: Blood Glucose; Diabetes Mellitus, Type 2; Female; Gliclazide; Hormones; Humans; Hypoglycemia; Hypogl | 1997 |
Rates of hypoglycemia in users of sulfonylureas.
Topics: Adult; Aged; Chlorpropamide; Female; Gliclazide; Glipizide; Glyburide; Humans; Hypoglycemia; Hypogly | 1997 |
Glimepiride: new preparation. Just another hypoglycaemic sulphonylurea agent.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Double-Blind Method; Drug Evalua | 1998 |
Comparison of capillary electrophoresis with HPLC for diagnosis of factitious hypoglycemia.
Topics: Adult; Chromatography, High Pressure Liquid; Diabetes Mellitus, Type 2; Drug Overdose; Electrophores | 2000 |
Possible interaction between gliclazide, fluconazole and sulfamethoxazole resulting in severe hypoglycaemia.
Topics: Anti-Infective Agents; Antifungal Agents; Diabetes Complications; Diabetes Mellitus; Drug Interactio | 2001 |
[Hypoglycemic complications of oral drug therapy of diabetes mellitus. 21 cases].
Topics: Age Factors; Aged; Diabetes Mellitus; Diabetic Coma; Drug Interactions; Female; Gliclazide; Glyburid | 1976 |
[3 cases of hypoglycemia during treatment with gliclazide (1): contribution of phaarmocokinetics to the development of pathogenetic hypotheses].
Topics: Adult; Aged; Female; Gliclazide; Humans; Hypoglycemia; Male; Sulfonylurea Compounds | 1977 |
[Sulfonylurea preparations and hypoglycemia].
Topics: Gliclazide; Humans; Hypoglycemia; Probability | 1992 |
A screening test for detecting sulfonylureas in plasma.
Topics: Aged; Aged, 80 and over; Chlorpropamide; Chromatography, High Pressure Liquid; Female; Gliclazide; G | 1990 |
Interaction between gliclazide and cimetidine.
Topics: Aged; Cimetidine; Drug Interactions; Gliclazide; Humans; Hypoglycemia; Male; Sulfonylurea Compounds | 1987 |